Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 53 clinical trials
Sj-subway a Predictor for the Recurrence of High-risk Hormone Receptor-positive Breast That is Sensitive to Extended Endocrine Therapy

Hormone receptor-positive breast cancer accounts for about 70% of all breast cancers. Extended endocrine therapy with aromatase inhibitor is the current main treatment for hormone receptor-positive breast cancer. However, previous studies have shown a long-lasting risk of the recurrence of hormone receptor-positive breast cancer at early stage, and disease recurrence …

estrogen
aromatase inhibitor
hormone therapy
progesterone
exemestane
  • 0 views
  • 30 Jul, 2021
  • 10 locations
Estrogen Receptor (ER) PET/CT Imaging in Breast Cancer

18F-Fluoroestradiol (18F-FES) is an estrogen receptor-targeting positron emission tomography tracer with high sensitivity and specificity for the detection of estrogen receptor(ER)-positive tumors . 18F-FES has been used as a predictive biomarker to demonstrate estrogen receptor heterogeneity , to evaluate the pharmacokinetics of estrogen receptor-targeted drugs , to measure residual estrogen …

  • 0 views
  • 14 Oct, 2022
  • 1 location
CTC Changes and Efficacy of Neoadjuvant Chemotherapy for Triple-negative Breast Cancer

Chemotherapy before operation for malignant tumors can reduce the size of tumors to a certain extent, even eliminate micrometastases. Chemotherapy can also detect the sensitivity of chemotherapeutic drugs and create opportunities for breast-conserving or surgical treatment for patients. This may lead to high survival opportunities for triple-negative breast cancer patients …

endocrine therapy
mammogram
paclitaxel
taxane
mastectomy
  • 1 views
  • 25 Mar, 2022
  • 2 locations